NO20083940L - Fremgangsmater for redusering av proteinaggregering - Google Patents
Fremgangsmater for redusering av proteinaggregeringInfo
- Publication number
- NO20083940L NO20083940L NO20083940A NO20083940A NO20083940L NO 20083940 L NO20083940 L NO 20083940L NO 20083940 A NO20083940 A NO 20083940A NO 20083940 A NO20083940 A NO 20083940A NO 20083940 L NO20083940 L NO 20083940L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- protein aggregation
- protein
- reducing protein
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Metoder for reduksjon av aggregering av et protein eller proteiner i en formulering, og proteinformuleringer som har reduserte aggregeringsegenskaper er gitt. Metodene og formuleringene beskrevet her opprettholder den biologiske aktiviteten til et protein og øker holdbarheten av proteinformuleringer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78413006P | 2006-03-20 | 2006-03-20 | |
PCT/US2007/006787 WO2007109221A2 (en) | 2006-03-20 | 2007-03-19 | Methods for reducing protein aggregation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083940L true NO20083940L (no) | 2008-10-16 |
Family
ID=38523027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083940A NO20083940L (no) | 2006-03-20 | 2008-09-16 | Fremgangsmater for redusering av proteinaggregering |
Country Status (18)
Country | Link |
---|---|
US (1) | US20080064856A1 (no) |
EP (1) | EP1996221A2 (no) |
JP (1) | JP2009530380A (no) |
KR (1) | KR20080108554A (no) |
CN (1) | CN101420972A (no) |
AR (1) | AR059964A1 (no) |
AU (1) | AU2007227408A1 (no) |
BR (1) | BRPI0709059A2 (no) |
CA (1) | CA2646934C (no) |
CR (1) | CR10290A (no) |
EC (1) | ECSP088758A (no) |
IL (1) | IL194123A0 (no) |
MX (1) | MX2008011888A (no) |
NO (1) | NO20083940L (no) |
PE (1) | PE20080121A1 (no) |
RU (1) | RU2008137634A (no) |
TW (1) | TW200806317A (no) |
WO (1) | WO2007109221A2 (no) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
ATE501248T1 (de) * | 2005-07-02 | 2011-03-15 | Arecor Ltd | Stabile wässrige systeme mit proteinen |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗il−13抗体製剤およびその使用 |
WO2009079837A1 (fr) * | 2007-12-18 | 2009-07-02 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Formulation pharmaceutique contenant une protéine de fusion sérum albumine humaine recombinante-interféron alpha |
PE20091174A1 (es) † | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
BRPI0907371A2 (pt) | 2008-01-09 | 2015-11-24 | Sanofi Aventis Deutschland | derivados de insulina com um perfil de tempo-ação muito retardado |
EP2113564A1 (en) * | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
KR101784231B1 (ko) | 2008-06-20 | 2017-11-08 | 노파르티스 아게 | 응집이 감소된 면역글로불린 |
CN102099809B (zh) | 2008-06-20 | 2014-05-07 | 诺华股份有限公司 | 识别蛋白质中大分子结合区域和易聚集区域的方法及其用途 |
JP5364310B2 (ja) * | 2008-07-14 | 2013-12-11 | アルフレッサファーマ株式会社 | 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬 |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
BRPI0918419A2 (pt) * | 2008-09-19 | 2015-11-24 | Hoffmann La Roche | nova formulação anticorpo |
HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
KR101763808B1 (ko) | 2009-06-04 | 2017-08-16 | 노파르티스 아게 | IgG 콘쥬게이션을 위한 자리의 확인 방법 |
ES2614161T3 (es) * | 2009-07-06 | 2017-05-29 | Sanofi-Aventis Deutschland Gmbh | Preparados acuosos de insulina que comprenden metionina |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
RU2537239C2 (ru) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
ES2582459T3 (es) | 2010-02-04 | 2016-09-13 | Biomarin Pharmaceutical Inc. | Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones |
CN107496917B (zh) * | 2010-02-26 | 2021-06-11 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
SG10201502398RA (en) | 2010-04-27 | 2015-05-28 | Scil Technology Gmbh | Stable MIA/CD-RAP formulations |
WO2011147921A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
JP6096675B2 (ja) * | 2011-01-04 | 2017-03-15 | アルチベル・ファルマ,ソシエダッド・リミターダ | 結核の治療又は予防に適切なリポソーム製剤 |
EA032625B1 (ru) * | 2011-05-02 | 2019-06-28 | Милленниум Фармасьютикалз, Инк. | КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
CN104411326B (zh) | 2012-01-12 | 2018-02-02 | 阿尔西维尔法尔玛公司 | 抗哮喘的mtb‑c疫苗 |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
US10132736B2 (en) | 2012-05-24 | 2018-11-20 | Abbvie Inc. | Methods for inspection of protein particles in a liquid beneficial agent |
WO2013179663A1 (ja) * | 2012-05-29 | 2013-12-05 | 日本ハム株式会社 | 食品成分抽出液および抽出方法 |
WO2014022817A2 (en) | 2012-08-03 | 2014-02-06 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
KR102202255B1 (ko) | 2012-11-20 | 2021-01-13 | 옵코 바이오로직스 리미티드 | 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법 |
KR102423377B1 (ko) | 2013-08-05 | 2022-07-25 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
US20150126444A1 (en) * | 2013-10-21 | 2015-05-07 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150158926A1 (en) * | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
ES2788870T3 (es) | 2014-08-04 | 2020-10-23 | Csl Ltd | Formulación de factor VIII |
CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
CN114796460A (zh) * | 2015-07-30 | 2022-07-29 | 生物马林药物股份有限公司 | C型利尿钠肽变体在治疗骨骼发育不良中的用途 |
CN108368482A (zh) | 2015-09-18 | 2018-08-03 | 特韦斯特生物科学公司 | 寡核酸变体文库及其合成 |
KR20180058772A (ko) | 2015-09-22 | 2018-06-01 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
SG10202100189WA (en) | 2016-07-11 | 2021-02-25 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
JP6854340B2 (ja) | 2016-08-22 | 2021-04-07 | ツイスト バイオサイエンス コーポレーション | デノボ合成された核酸ライブラリ |
KR102217487B1 (ko) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | 핵산 기반 데이터 저장 |
EP3586255A4 (en) | 2017-02-22 | 2021-03-31 | Twist Bioscience Corporation | NUCLEIC ACID-BASED DATA STORAGE |
GB201703063D0 (en) | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
CA3066744A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
CA3075505A1 (en) | 2017-09-11 | 2019-03-14 | Twist Bioscience Corporation | Gpcr binding proteins and synthesis thereof |
GB2583590A (en) | 2017-10-20 | 2020-11-04 | Twist Bioscience Corp | Heated nanowells for polynucleotide synthesis |
JP7158015B2 (ja) | 2017-11-09 | 2022-10-21 | 国立研究開発法人産業技術総合研究所 | ポリペプチドの凝集化抑制方法 |
AU2019265005A1 (en) | 2018-05-10 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
AU2019270243A1 (en) | 2018-05-18 | 2021-01-07 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US20210187107A1 (en) * | 2018-08-29 | 2021-06-24 | Glaxosmithkline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
SG11202109283UA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for antibody optimization |
WO2020176678A1 (en) * | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
CN114729342A (zh) | 2019-06-21 | 2022-07-08 | 特韦斯特生物科学公司 | 基于条形码的核酸序列装配 |
US20220227824A1 (en) * | 2019-06-24 | 2022-07-21 | The Children's Hospital Of Philadelphia | Use of srrd in the inhibition of protein aggregation |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
US20220251186A1 (en) * | 2019-07-11 | 2022-08-11 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling |
AU2021330845A1 (en) * | 2020-08-24 | 2023-01-19 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
WO2022099223A2 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
WO2024058201A1 (ja) * | 2022-09-16 | 2024-03-21 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5516964A (en) * | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
KR100826621B1 (ko) * | 1997-09-23 | 2008-05-02 | 렌트슐러 비오테히놀로기 게엠베하 | 액상 인터페론-베타 제제 |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
EP1368486A4 (en) * | 1999-07-15 | 2009-04-01 | Genetics Inst Llc | IL-11 FORMULATIONS |
CZ20021186A3 (cs) * | 1999-10-04 | 2002-11-13 | Chiron Corporation | Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid |
US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
WO2002011695A2 (en) * | 2000-08-07 | 2002-02-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
EP1351704B1 (en) * | 2000-12-21 | 2007-03-07 | Nektar Therapeutics | Storage stable powder compositions of interleukin-4 receptor |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US7051050B2 (en) * | 2002-03-19 | 2006-05-23 | Netwrok Appliance, Inc. | System and method for restoring a single file from a snapshot |
US20040022792A1 (en) * | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
CA2490342C (en) * | 2002-06-21 | 2015-06-16 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
EP1599222B1 (en) * | 2003-01-08 | 2009-03-04 | Novartis Vaccines and Diagnostics, Inc. | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
CA2551510C (en) * | 2003-12-23 | 2013-07-30 | Pharmacia Corporation | Stable growth hormone liquid formulation |
CA2567309A1 (en) * | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
EA010979B1 (ru) * | 2004-06-01 | 2008-12-30 | Арес Трейдинг С.А. | Стабилизированные жидкие препаративные формы интерферона |
PE20061201A1 (es) * | 2005-01-28 | 2006-11-03 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido |
-
2007
- 2007-03-08 TW TW096108014A patent/TW200806317A/zh unknown
- 2007-03-16 PE PE2007000286A patent/PE20080121A1/es not_active Application Discontinuation
- 2007-03-19 CN CNA2007800132437A patent/CN101420972A/zh active Pending
- 2007-03-19 MX MX2008011888A patent/MX2008011888A/es not_active Application Discontinuation
- 2007-03-19 AR ARP070101104A patent/AR059964A1/es unknown
- 2007-03-19 KR KR1020087025501A patent/KR20080108554A/ko not_active Application Discontinuation
- 2007-03-19 WO PCT/US2007/006787 patent/WO2007109221A2/en active Application Filing
- 2007-03-19 JP JP2009501487A patent/JP2009530380A/ja active Pending
- 2007-03-19 BR BRPI0709059-5A patent/BRPI0709059A2/pt not_active IP Right Cessation
- 2007-03-19 US US11/725,534 patent/US20080064856A1/en not_active Abandoned
- 2007-03-19 RU RU2008137634/15A patent/RU2008137634A/ru not_active Application Discontinuation
- 2007-03-19 EP EP07753416A patent/EP1996221A2/en not_active Ceased
- 2007-03-19 AU AU2007227408A patent/AU2007227408A1/en not_active Abandoned
- 2007-03-19 CA CA2646934A patent/CA2646934C/en not_active Expired - Fee Related
-
2008
- 2008-09-16 IL IL194123A patent/IL194123A0/en unknown
- 2008-09-16 NO NO20083940A patent/NO20083940L/no unknown
- 2008-09-16 CR CR10290A patent/CR10290A/es not_active Application Discontinuation
- 2008-09-22 EC EC2008008758A patent/ECSP088758A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1996221A2 (en) | 2008-12-03 |
WO2007109221A9 (en) | 2007-12-06 |
JP2009530380A (ja) | 2009-08-27 |
BRPI0709059A2 (pt) | 2011-06-21 |
CA2646934A1 (en) | 2007-09-27 |
WO2007109221A2 (en) | 2007-09-27 |
US20080064856A1 (en) | 2008-03-13 |
IL194123A0 (en) | 2011-08-01 |
ECSP088758A (es) | 2008-10-31 |
MX2008011888A (es) | 2008-09-29 |
PE20080121A1 (es) | 2008-03-05 |
AU2007227408A1 (en) | 2007-09-27 |
WO2007109221A3 (en) | 2008-02-21 |
CR10290A (es) | 2008-11-26 |
CA2646934C (en) | 2014-09-23 |
TW200806317A (en) | 2008-02-01 |
CN101420972A (zh) | 2009-04-29 |
AR059964A1 (es) | 2008-05-14 |
KR20080108554A (ko) | 2008-12-15 |
RU2008137634A (ru) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083940L (no) | Fremgangsmater for redusering av proteinaggregering | |
NO20075992L (no) | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav | |
NO20083324L (no) | Multisykliske aminosyrederivater og anvendelse derav | |
NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
ATE542553T1 (de) | Dezellularisierte omentummatrix und ihre verwendung | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
NO20091413L (no) | WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser | |
IL211085A0 (en) | Perfusion solution | |
NO20081878L (no) | Diacylindazolderivater som lipase- og fosfolipaseinhibitorer | |
CY1112383T1 (el) | Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap) | |
ATE525913T2 (de) | Fettzusammensetzungen | |
WO2007019176A3 (en) | Corn protein concentrates | |
DE602005026031D1 (de) | Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen | |
BRPI0511396A (pt) | derivados de retinal e métodos para uso no tratamento de enfermidades visuais | |
NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
NO20082376L (no) | Farmasoytiske sammensetninger | |
NO20090305L (no) | Cyklosporin formuleringer | |
DK1498039T3 (da) | Vitale cellepræparater, som indeholder mælkesyrebakterie som aktivt stof, og mælkesyrebakterieholdige fødevareprodukter | |
NO20060955L (no) | Farmasoytisk sammensetning som er nyttig til stamcellemobilisering | |
BR112014014319A2 (pt) | composições de cuidado oral | |
NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
CR10050A (es) | Combinacion fungicida de productos activos | |
ATE433459T1 (de) | Desoxo-nonadepsipeptide | |
NO20080034L (no) | Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer |